title: Clinical characteristics and outcomes after 5 years pro re nata treatment of neovascular age-related macular degeneration with ranibizumab.
authors.affiliation: Academic Unit of Ophthalmology, York Teaching Hospitals NHS Foundation Trust, York, North Yorkshire, UK.
authors.forename: Archana
authors.initials: A
authors.lastname: Airody
authors.affiliation: Academic Unit of Ophthalmology, York Teaching Hospitals NHS Foundation Trust, York, North Yorkshire, UK.
authors.forename: Divya
authors.initials: D
authors.lastname: Venugopal
authors.affiliation: Department of Health Sciences, University of York, York, North Yorkshire, UK.
authors.forename: Victoria
authors.initials: V
authors.lastname: Allgar
authors.affiliation: Academic Unit of Ophthalmology, York Teaching Hospitals NHS Foundation Trust, York, North Yorkshire, UK.
authors.forename: Richard P
authors.initials: RP
authors.lastname: Gale
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab / Q000627:therapeutic use*; D012160:Retina / Q000473:pathology; D012189:Retrospective Studies; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab